文献速递卫生政策与健康促进

治疗羟考酮使用障碍的候选疫苗的临床前安全性与毒理学特征

Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.
PubMed 文献 · Vaccine · 2022-04-22

本研究对吸附于铝佐剂的Oxy(Gly)4-sKLH结合疫苗进行了GLP毒理学研究,Sprague Dawley大鼠每两周接种一次共四次,低剂量和高剂量分别相当于1倍和47倍人用剂量。结果显示疫苗诱导高抗体滴度,未观察到疫苗相关的血液学、临床化学、尿液分析、体重、器官重量或解剖病理学毒理学发现,表明该疫苗在大鼠中耐受良好且具有免疫原性。

要点

  • Oxy(Gly)4-sKLH疫苗在大鼠中诱导高抗体滴度,低剂量亦具免疫原性。
  • 未观察到疫苗相关的血液学、临床化学、尿液分析、体重、器官重量或解剖病理学毒理学发现。
  • 疫苗在大鼠中耐受良好,不产生不良副作用。

核心结论

  • Oxy(Gly)4-sKLH疫苗在大鼠中耐受良好,低剂量亦具免疫原性,不产生不良副作用。

研究设计与样本

  • GLP毒理学研究,使用Sprague Dawley大鼠,接种铝佐剂或吸附于铝佐剂的疫苗,低剂量和高剂量分别相当于1倍或47倍人用剂量,每两周接种一次共四次。

主要发现

  • 低剂量和高剂量疫苗均诱导高抗体滴度。
  • 未观察到Oxy(Gly)4-sKLH相关的血液学、临床化学、尿液分析、体重、器官重量或解剖病理学毒理学发现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Opioid use disorders (OUD) and overdose represent a public health threat, resulting in thousands of deaths annually worldwide. Vaccines offer a promising treatment for OUD and potentially the prevention of fatal overdoses. The Oxy(Gly)4-sKLH Conjugate Vaccine, Adsorbed (Oxy(Gly)4-sKLH) has shown promising pre-clinical efficacy at reducing the behavioral and pharmacological effects of oxycodone. To support its clinical evaluation, a GLP toxicology study was performed to address the safety of Oxy(Gly)4-sKLH. Sprague Dawley rats were vaccinated with either aluminum adjuvant (alum) or vaccine adsorbed on alum. Low and high doses of Oxy(Gly)4-sKLH, equivalent to a 1X or 47X human dose, respectively, were administered every two weeks for a total of four vaccinations. Both vaccine doses induced high antibody titers. Vaccine-related toxicity was assessed postmortem in one experimental group after receiving the fourth immunization of the vaccine's high dose. For the remaining experimental groups, rats were challenged with 1.5 mg/kg/day s.c. oxycodone for 7 days after the fourth vaccination to assess whether concurrent exposure to oxycodone in vaccinated animals resulted in toxicity. All rats, except a subset of the aluminum control and the high dose vaccine groups, were sacrificed following oxycodone exposure. These subsets were allowed a four weeks recovery period prior to euthanasia. In this study, no Oxy(Gly)4-sKLH-related hematology, clinical chemistry, urinalysis, body weight, organ weight, or anatomic pathology toxicological findings were observed. These results demonstrate that the Oxy(Gly)4-sKLH vaccine is well tolerated, is immunogenic even at low doses, and does not produce undesired side effects in rats.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hamid FA, Marker CL, Raleigh MD, et al. Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. Vaccine. 2022. PMID: 35469698. doi:10.1016/j.vaccine.2022.03.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。